Novo Nordisk(US:NVO) GLP1减重宝典·2026-02-25 12:40Core Viewpoint - Novo Nordisk's innovative drug amycretin shows promising results in weight loss for overweight and obese individuals, with significant efficacy and safety demonstrated in clinical trials [6][7][9]. Group 1: Clinical Trial Results - The clinical trial results for amycretin were presented at the 85th American Diabetes Association (ADA) Scientific Sessions, highlighting its effectiveness in weight reduction [6]. - In a 36-week trial, the 60 mg dose of amycretin resulted in a weight loss of -24.3% compared to a -1.1% loss in the placebo group, while the 20 mg group achieved -22.0% [7]. - The study indicated that all dosage groups showed no plateau in weight loss curves by the end of the treatment period, suggesting potential for further weight loss with extended treatment [7]. Group 2: Safety and Tolerability - Amycretin demonstrated excellent tolerability at the 60 mg dose, with safety profiles consistent with existing GLP-1 and incretin receptor agonists [7]. - Adverse reactions were primarily gastrointestinal and showed a dose-dependent increase, but most were mild to moderate and resolved by the end of the trial [7]. - The oral formulation of amycretin also showed significant weight loss, with participants losing an average of 10.4% and 13.1% in two different dosing regimens over 12 weeks, compared to 1.2% in the placebo group [8]. Group 3: Development and Future Prospects - Amycretin is a long-acting single-molecule formulation that activates both GLP-1 and incretin receptors, providing a synergistic effect on appetite regulation for overweight or obese adults and type 2 diabetes patients [9]. - Novo Nordisk is accelerating the development of both the injectable and oral forms of amycretin, with ongoing phase 3 clinical trials to evaluate its potential as a next-generation weight management solution [9].